We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD Gets Enterprise Level Cybersecurity Assessment From UL
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced an enterprise level cybersecurity assessment by the UL Healthcare. This ensures that all medical devices developed by the company will be in line with the UL Cybersecurity Assurance Program (“UL CAP”).
The company received UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software. The UL CAP version of the BD FACSLyric flow cytometer will be available in 2019.
What is UL CAP?
UL CAP incorporates the UL 2900 set of standards, including UL 2900-1. This is a software cybersecurity standard for network-connected medical devices that has official recognition from the FDA.
More about BD FACSLyric Flow Cytometer
The BD FACSLyric flow cytometer, used with BD Multitest assays, is intended for immunological assessment of individuals and patients having immune deficiency.
Price Performance
In the past year, BD has outperformed the industry to which it belongs in terms of share price. The company’s shares have returned 8.1% compared with the industry’s 2.7% decline. However, the current return is marginally lower than the S&P 500’s decrease of 0.9%. The stock has a Zacks Rank #3 (Hold).
Product Portfolio Solid
A diverse product portfolio is a key catalyst for BD. Recently, BD announced the launch of BD FACSymphony S6 cell sorter, which was displayed at the 33rd Congress of the International Society for Advancement of Cytometry in Prague. Per management, the new platform enables researchers to sort cell populations to better study cell phenotypes for immunology and multi-omics research.
BD’s Alaris Pump and Pyxis ES in the Medical segment, BD MAX, BD FACSLyric continue to boost results. Management is also optimistic about consistent expansion of the BD Horizon Brilliant dyes in Life Sciences and Lutonix AV and Covera in the Interventional segment.
Additionally, BD announced the plan for commercial availability of BD Synapsys microbiology informatics solution, which provides laboratories with secure connectivity across instruments and locations. Additionally, management confirmed that the company is on track to provide sodium chloride saline to customers through a partnership with Fresenius Medical Care.
Management has confirmed that there are newer products in the company’s pipe line.
Stocks to Consider
A few better-ranked stocks in the broader medical space are Quidel Corporation (QDEL - Free Report) , STAAR Surgical Company (STAA - Free Report) and Illumina, Inc (ILMN - Free Report) .
With a Zacks Rank #1, STAAR Surgical delivered average four-quarter positive earnings surprise of 400%.
Illumina’s long-term earnings growth rate is projected at 23.4%. The stock carries a Zacks Rank #2 (Buy).
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
BD Gets Enterprise Level Cybersecurity Assessment From UL
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced an enterprise level cybersecurity assessment by the UL Healthcare. This ensures that all medical devices developed by the company will be in line with the UL Cybersecurity Assurance Program (“UL CAP”).
The company received UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software. The UL CAP version of the BD FACSLyric flow cytometer will be available in 2019.
What is UL CAP?
UL CAP incorporates the UL 2900 set of standards, including UL 2900-1. This is a software cybersecurity standard for network-connected medical devices that has official recognition from the FDA.
More about BD FACSLyric Flow Cytometer
The BD FACSLyric flow cytometer, used with BD Multitest assays, is intended for immunological assessment of individuals and patients having immune deficiency.
Price Performance
In the past year, BD has outperformed the industry to which it belongs in terms of share price. The company’s shares have returned 8.1% compared with the industry’s 2.7% decline. However, the current return is marginally lower than the S&P 500’s decrease of 0.9%. The stock has a Zacks Rank #3 (Hold).
Product Portfolio Solid
A diverse product portfolio is a key catalyst for BD. Recently, BD announced the launch of BD FACSymphony S6 cell sorter, which was displayed at the 33rd Congress of the International Society for Advancement of Cytometry in Prague. Per management, the new platform enables researchers to sort cell populations to better study cell phenotypes for immunology and multi-omics research.
BD’s Alaris Pump and Pyxis ES in the Medical segment, BD MAX, BD FACSLyric continue to boost results. Management is also optimistic about consistent expansion of the BD Horizon Brilliant dyes in Life Sciences and Lutonix AV and Covera in the Interventional segment.
Additionally, BD announced the plan for commercial availability of BD Synapsys microbiology informatics solution, which provides laboratories with secure connectivity across instruments and locations. Additionally, management confirmed that the company is on track to provide sodium chloride saline to customers through a partnership with Fresenius Medical Care.
Management has confirmed that there are newer products in the company’s pipe line.
Stocks to Consider
A few better-ranked stocks in the broader medical space are Quidel Corporation (QDEL - Free Report) , STAAR Surgical Company (STAA - Free Report) and Illumina, Inc (ILMN - Free Report) .
Quidel has long-term expected earnings growth rate of 25% and sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
With a Zacks Rank #1, STAAR Surgical delivered average four-quarter positive earnings surprise of 400%.
Illumina’s long-term earnings growth rate is projected at 23.4%. The stock carries a Zacks Rank #2 (Buy).
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>